<DOC>
	<DOC>NCT01011959</DOC>
	<brief_summary>This is a randomized study of the safety and tolerability of multiple doses of REGN88 in rheumatoid arthritis patients who are receiving treatment with methotrexate.</brief_summary>
	<brief_title>A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects</brief_title>
	<detailed_description>This is a multi-centered, randomized, double-blind, placebo-controlled, ascending parallel-group study of the safety and tolerability of REGN88 in patients with rheumatoid arthritis who are receiving concomitant methotrexate. This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will not begin until enrollment in Part B is complete.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Patients with an established diagnosis of Rheumatoid Arthritis Patients currently treated with concomitant methotrexate for at least 12 weeks, with a stable dose for at least 6 weeks Persistent chronic or current active infections Patients who have taken anakinra within 2 weeks Patients who have taken etanercept, cyclosporine, mycophenolate, tacrolimus, gold, penicillamine, sulfasalazine or hydroxychloroquine within 4 weeks Patients who have taken adalimumab within 6 weeks Patients who have taken abatacept, azathioprine, cyclophosphamide or infliximab within 12 weeks Patients who have taken leflunomide or rituximab within 6 months Patients who have had prior treatment with tocilizumab or any other antiIL6 medication Significant arthritis or other medical condition that could interfere with study evaluations Participation in any clinical research study evaluating another investigational drug within 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>